Sanofi-Aventis To Appeal Lovenox Verdict

Law360, New York (February 13, 2007, 12:00 AM EST) -- Sanofi-Aventis will appeal a district court's ruling that its patent for anti-clotting drug Lovenox is unenforceable, Sanofi-Aventis' chief executive said Tuesday.

Sanofi-Aventis' patent infringement lawsuit against generic drug makers Amphastar Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc. was dismissed on Feb. 9. U.S. District Court Judge Mariana R. Pfaelzer ruled that Sanofi-Aventis was deceptive when it applied for its patent of the drug.

“We will strongly defend this patent and we will appeal,” Sanofi-Aventis Chief Executive Officer Gerard Le Fur said at an analysts’ meeting Tuesday....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.